Hydroxamate, a key pharmacophore exhibiting a wide range of biological activities

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1311-1326

  Bertrand, Samuel ^a   Hélesbeux, Jean Jacques ^a   Larcher, Gérald ^b   Duval, Olivier ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Biological activities; Hydroxamates; Hydroxamic acid derivatives; Metal chelators; Metallo enzyme inhibitors

Indexed keywords

DEFEROXAMINE; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; HYDROXYLAMINE; IRON; MATRIX METALLOPROTEINASE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ACYLATION; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL GROWTH; BIOLOGICAL ACTIVITY; DRUG DESIGN; DRUG DETOXIFICATION; DRUG STABILITY; HEART PROTECTION; HUMAN; IRON OVERLOAD; OXIDATION; PHARMACOPHORE; RETINA DEGENERATION; REVIEW;

ANIMALS; HUMANS; HYDROXAMIC ACIDS;

EID: 84881493943     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113139990007     Document Type: Review

References (201)

1. Hider, R. C.; Kong, X. Chemistry and biology of siderophores. Nat. Prod. Rep., 2010, 27(5), 637-657.
2. Renshaw, J. C.; Robson, G. D.; Trinci, A. P. J.; Wiebe, M. G.; Livens, F. R.; Collison, D.; Taylor, R. J. Fungal siderophores: structures, functions and applications. Mycol. Res., 2002, 106(10), 1123-1142.
3. Meyer, J.-M. Pyoverdines: pigments, siderophores and potential taxonomic markers of fluorescent Pseudomonas species. Arch. Microbiol., 2000, 174, 135-142.
4. Crosa, J. H.; Mey, A. R.; Payne, S. M., Iron transport in bacteria. ASM Press: Washington DC, 2004
5. α-methyl coprogen B, a potential marker of the airway colonization by Scedosporium apiospermum in patients with cystic fibrosis. Med. Mycol., 2010, 48(O1), S98-S107.
6. Armstrong, J. E.; Van Baalen, C. Iron Transport in Microalgae: the Isolation and Biological Activity of a Hydroxamate Siderophore from the Blue-Green Alga Agmenellum quadruplicatum. J. Gen. Microbiol., 1979, 111(2), 253-262.
7. Trick, C. G.; Andersen, R. J.; Gillam, A.; Harrison, P. J. Prorocentrin: An Extracellular Siderophore Produced by the Marine Dinoflagellate Prorocentrum minimum. Science, 1983, 219(4582), 306-308.
8. Hissen, A. H. T.; Wan, A. N. C.; Warwas, M. L.; Pinto, L. J.; Moore, M. M. The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence. Infect. Immun., 2005, 73(9), 5493-5503.
9. Sicker, D.; Schulz, M. In: Bioactive Natural Products (Part H); Atta-Ur-Rahman, Ed., Elsevier: 2002; Vol. 27, Part 8, pp. 185-232.
10. Alipieva, K. I.; Taskova, R. M.; Evstatieva, L. N.; Handjieva, N. V.; Popov, S. S. Benzoxazinoids and iridoid glucosides from four Lamium species. Phytochemistry, 2003, 64(8), 1413-1417.
11. Bravo, H. R.; Copaja, S. V.; Argandoña, V. H. Chemical Basis for the Antifeedant Activity of Natural Hydroxamic Acids and Related Compounds. J. Agric. Food Chem., 2004, 52(9), 2598-2601.
12. Zhou, T.; Ma, Y.; Kong, X.; Hider, R. C. Design of iron chelators with therapeutic application. Dalton Trans., 2012, 41(21), 6371-6389.
13. Muller, G.; Raymond, K. N. Specificity and mechanism of ferrioxamine-mediated iron transport in Streptomyces pilosus. J. Bacteriol., 1984, 160(1), 304-312.
14. Codd, R. Traversing the coordination chemistry and chemical biology of hydroxamic acids. Coord. Chem. Rev., 2008, 252(12-14), 1387-1408.
15. Lou, B.; Yang, K. Molecular Diversity of Hydroxamic Acids: Part II. Potential Therapeutic Applications. Mini-Rev. Med. Chem., 2003, 3(6), 609-620.
16. Saban, N.; Bujak, M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemther. Pharmacol., 2009, 64(2), 213-221.
17. Pradines, B.; Tall, A.; Ramiandrasoa, F.; Spiegel, A.; Sokhna, C.; Fusai, T.; Mosnier, J.; Daries, W.; Trape, J. F.; Kunesch, G.; Parzy, D.; Rogier, C. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. J. Antimicrob. Chemother., 2006, 57(6), 1093-1099.
18. Marmion, C. J.; Griffith, D.; Nolan, K. B. Hydroxamic acids - An intriguing family of enzyme inhibitors and biomedical ligands. Eur. J. Inorg. Chem., 2004, (15), 3003-3016.
19. ten Holte, P.; van Emelen, K.; Janicot, M.; Fong, P. C.; de Bono, J. S.; Arts, J. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. Top. Med. Chem., 2007, 1, 293-331.
20. Plewe, M. B.; Butler, S. L.; R. Dress, K.; Hu, Q.; Johnson, T. W.; Kuehler, J. E.; Kuki, A.; Lam, H.; Liu, W.; Nowlin, D.; Peng, Q.; Rahavendran, S. V.; Tanis, S. P.; Tran, K. T.; Wang, H.; Yang, A.; Zhang, J. Azaindole Hydroxamic Acids are Potent HIV-1 Integrase Inhibitors. J. Med. Chem., 2009, 52(22), 7211-7219.
21. Shigeura, H. T.; Gordon, C. N. Further Studies on the Activity of Hadacidin. Cancer Res., 1962, 22, 1356-1361.
22. Möllmann, U.; Heinisch, L.; Bauernfeind, A.; Köhler, T.; Ankel- Fuchs, D. Siderophores as drug delivery agents: application of the Trojan Horse strategy. BioMetals, 2009, 22(4), 615-624.
23. Aniya, Y.; Ohtani, I. I.; Higa, T.; Miyagi, C.; Gibo, H.; Shimabukuro, M.; Nakanishi, H.; Taira, J. Dimerumic acid as an antioxidant of the mold, Monascus Anka. Free Rad. Biol. Med., 2000, 28(6), 999-1004.
24. Donepudi, S.; Mattison, R. J.; Kihslinger, J. E.; Godley, L. A. Modulators of DNA methylation and histone acetylation. Update Cancer Ther., 2007, 2(4), 157-169.
25. Jazirehi, A. R. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti-Cancer Drugs, 2010, 21(9), 805-813.
26. Richardson, D. R.; Kalinowski, D. S.; Lau, S.; Jansson, P. J.; Lovejoy, D. B. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumor agents. Biochim. Biophys. Acta - Gen. Subj., 2009, 1790(7), 702-717.
27. Henle, E. S.; Linn, S. Formation, Prevention, and Repair of DNA Damage by Iron/Hydrogen Peroxide. J. Biol. Chem., 1997, 272(31), 19095-19098.
28. Aust, S. D.; White, B. C. Iron chelation prevents tissue injury following ischemia. Adv. Free Rad. Biol. Med., 1985, 1(1), 1-17.
29. McLaren, G.; Gordeuk, V. Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hematology, 2009, 2009(1), 195-206.
30. Savulescu, J. Thalassaemia major: the murky story of deferiprone. British Med. J., 2004, 328, 358-359.
31. Loukopoulos, D. In: Management of the haemoglobinopathies, In: Congress of the European Haematology Association, Birmingham, UK, 25-28 June 2000, 2000; pp. 141-145.
32. Ackrill, P.; Day, J. P.; Ahmed, R. Aluminum and iron overload in chronic dialysis. Kidney int. Suppl., 1988, 24, S163-167.
33. Hayflick, S. J. Neurodegeneration With Brain Iron Accumulation: From Genes to Pathogenesis. Sem. Pediatr. Neurol., 2006, 13(3), 182-185.
34. Quintana, C.; Bellefqih, S.; Laval, J. Y.; Guerquin-Kern, J. L.; Wu, T. D.; Avila, J.; Ferrer, I.; Arranz, R.; Patiño, C. Study of localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol., 2006, 153, 42-53.
35. Bartzokis, G.; Lu, P. H.; Tishler, T. A.; Fong, S. M.; Oluwadara, B.; Finn, J. P.; Huang, D.; Bordelon, Y.; Mintz, J.; Perlman, S. Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochem. Res., 2007, 32(10), 1655-1664.
36. Burgetova, A.; Seidl, Z.; Krasensky, J.; Horakova, D.; Vaneckova, M. Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T 2 Relaxometry. Eur. Neurol., 2010, 63(3), 136-143.
37. Dexter, D. T.; Wells, F. R.; Lee, A. J.; Agid, F.; Agid, Y.; Jenner, P.; Marsden, C. D. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease. J. Neurochem., 1989, 52(6), 1830-1836.
38. Kakhlon, O.; Breuer, B.; Munnich, A.; Cabantchik, Z. I. In: Oxidative Stress and Free Radical Damage in Neurology; Gadoth, Natan; Göbel, Hans Hilmar, Humana Press: 2011; pp. 169-190.
39. Hershko, C. Oral iron chelators: new opportunities and new dilemmas. Haematologica, 2006, 91(10), 1307-1312.
40. Farkas, E.; Enyedy, E. A.; Csóka, H. Some factors affecting metal ion-monohydroxamate interactions in aqueous solution. J. Inorg. Biochem., 2000, 79(1-4), 205-211.
41. Jones, M. M. New developments in therapeutic chelating agents as antidotes for metal poisoning. Crit. Rev. Toxicol., 1991, 21(3), 209-233.
42. Nagoba, B.; Vedpathak, D. Medical Applications of Siderophores. Eur. J. Gen. Med., 2011, 8(3), 229-235.
43. Shimoni, E.; Ampel, M.; Zähner, H.; Neeman, I. Antioxidant properties of desferrioxamine E, a new hydroxamate antioxidant. J. Am. Oil Chem. Soc., 1998, 75(10), 1453-1455.
44. Adgent, M. A.; Squadrito, G. L.; Ballinger, C. A.; Krzywanski, D. M.; Lancaster, J. R.; Postlethwait, E. M. Desferrioxamine inhibits protein tyrosine nitration: Mechanisms and implications. Free Rad. Biol. Med., 2012, 53(4), 951-961.
45. Rha, H. J.; Bae, I. Y.; Lee, S.; Yoo, S.-H.; Chang, P.-S.; Lee, H. G. Enhancement of anti-radical activity of pectin from apple pomace by hydroxamation. Food Hydrocolloid., 2011, 25(3), 545-548.
46. Kwak, S.-Y.; Lee, S.; Choi, H.-R.; Park, K.-C.; Lee, Y.-S. Dual effects of caffeoyl-amino acidyl-hydroxamic acid as an antioxidant and depigmenting agent. Bioorg. Med. Chem. Lett., 2011, 21(18), 5155-5158.
47. Sato, E.; Kohno, M.; Nakashima, T.; Niwano, Y. Ciclopirox olamine directly scavenges hydroxyl radical. Int. J. Dermatol., 2008, 47(1), 15-18.
48. Hašková, P.; Koubková, L.; Vávrová, A.; Macková, E.; Hrušková, K.; Kovaríková, P.; Vávrová, K.; Šimunek, T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicol., 2011, 289(2-3), 122-131.
49. Oxidative Stress and Free Radical Damage in Neurology. 1st; Humana Press: 2011
50. Obolensky, A.; Berenshtein, E.; Lederman, M.; Bulvik, B.; Alper- Pinus, R.; Yaul, R.; Deleon, E.; Chowers, I.; Chevion, M.; Banin, E. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa. Free Rad. Biol. Med., 2011, 51(8), 1482-1491.
51. Taira, J.; Miyagi, C.; Aniya, Y. Dimerumic acid as an antioxidant from the mold, Monascus anka: the inhibition mechanisms against lipid peroxidation and hemeprotein-mediated oxidation. Biochem. Pharmacol., 2002, 63(5), 1019-1026.
52. Al-Harbi, M. M.; Al-Gharably, N. M.; Al-Shabanah, O. A.; Al- Bekairi, M. M.; Osman, A. M. M.; Tawfik, H. N. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemther. Pharmacol., 1992, 31(3), 200-204.
53. Weinberg, E. D.; Moon, J. Malaria and iron: history and review. Drug Metab. Rev., 2009, 41(4), 644-662.
54. Tsafack, A.; Loyevsky, M.; Ponka, P.; Cabantchik, Z. I. Mode of action of iron (III) chelators as antimalarials: IV, Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J. Lab. Clin. Med., 1996, 127(6), 574-582.
55. Mabeza, G. F.; Loyevsky, M.; Gordeuk, V. R.; Weiss, G. Iron chelation therapy for malaria: A review. Pharmacol. Ther., 1999, 81(1), 53-75.
56. Andrews, K. T.; Haque, A.; Jones, M. K. HDAC inhibitors in parasitic diseases. Immunol. Cell Biol., 2012, 90(1), 66-77.
57. Skinner-Adams, T. S.; Peatey, C. L.; Anderson, K.; Trenholme, K. R.; Krige, D.; Brown, C. L.; Stack, C.; Nsangou, D. M. M.; Mathews, R. T.; Thivierge, K.; Dalton, J. P.; Gardiner, D. L. The Aminopeptidase Inhibitor CHR-2863 Is an Orally Bioavailable Inhibitor of Murine Malaria. Antimicrob. Agents Chemother., 2012, 56(6), 3244-3249.
58. Flipo, M.; Beghyn, T.; Leroux, V.; Florent, I.; Deprez, B. P.; Deprez-Poulain, R. F. Novel Selective Inhibitors of the Zinc Plasmodial Aminopeptidase PfA-M1 as Potential Antimalarial Agents. J. Med. Chem., 2007, 50(6), 1322-1334.
59. Mishra, R. C.; Tripathi, R.; Katiyar, D.; Tewari, N.; Singh, D.; Tripathi, R. P. Synthesis of glycosylated β-amino hydroxamates as new class of antimalarials. Bioorg. Med. Chem., 2003, 11(24), 5363-5374.
60. Bergeron, R. J.; Elliott, G. T.; Kline, S. J.; Ramphal, R.; III, L. S. J. Bacteriostatic and Fungostatic Action of Catecholamide Iron Chelators. Antimicrob. Agents Chemother., 1983, 24(5), 725-730.
61. Boelaert, J. R.; de Locht, M.; van Cutsem, J.; Kerrels, V.; Cantinieaux, B.; Verdonck, A.; van Landuyt, H. W.; Schneider, Y. J. Mucormycosis during deferoxamine therapy is a siderophoremediated infection. In vitro and in vivo animal studies. J. Clin. Invest., 1993, 91(5), 1979.
62. Winum, J.-Y.; Köhler, S.; Scozzafava, A.; Montero, J.-L.; Supuran, C. T. Targeting bacterial metalloenzymes: A new strategy for the development of anti-infective agents. Anti-Infect. Agents Med. Chem., 2008, 7(3), 169-179.
63. Jain, R.; Chen, D.; White, R. J.; Patel, D. V.; Yuan, Z. Bacterial peptide deformylase inhibitors: A new class of antibacterial agents. Curr. Med. Chem., 2005, 12(14), 1607-1621.
64. Schiffmann, R.; Neugebauer, A.; Klein, C. D. Metal-Mediated Inhibition of Escherichia coli Methionine Aminopeptidase: Structure-Activity Relationships and Development of a Novel Scoring Function for Metal-Ligand Interactions. J. Med. Chem., 2005, 49(2), 511-522.
65. Hu, X.; Zhu, J.; Srivathsan, S.; Pei, D. Peptidyl hydroxamic acids as methionine aminopeptidase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(1), 77-79.
66. Brown, M. F.; Reilly, U.; Abramite, J. A.; Arcari, J. T.; Oliver, R.; Barham, R. A.; Che, Y.; Chen, J. M.; Collantes, E. M.; Chung, S. W.; Desbonnet, C.; Doty, J.; Doroski, M.; Engtrakul, J. J.; Harris, T. M.; Huband, M.; Knafels, J. D.; Leach, K. L.; Liu, S.; Marfat, A.; Marra, A.; McElroy, E.; Melnick, M.; Menard, C. A.; Montgomery, J. I.; Mullins, L.; Noe, M. C.; O'Donnell, J.; Penzien, J.; Plummer, M. S.; Price, L. M.; Shanmugasundaram, V.; Thoma, C.; Uccello, D. P.; Warmus, J. S.; Wishka, D. G. Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections. J. Med. Chem., 2012, DOI: 10.1021/jm2014748.
67. Ly, H. D.; Clugston, S. L.; Sampson, P. B.; Honek, J. F. Sytheses and Kinetic Evaluation of Hydroxamate-based peptide inhibitors of Glyoxalase I. Bioorg. Med. Chem. Lett., 1998, 8(7), 705-710.
68. Daher, R.; Coinc-on, M.; Fonvielle, M.; Gest, P. M.; Guerin, M. E.; Jackson, M.; Sygusch, J.; Therisod, M. Rational Design, Synthesis, and Evaluation of New Selective Inhibitors of Microbial Class II (Zinc Dependent) Fructose Bis-phosphate Aldolases. J. Med. Chem., 2010, 53(21), 7836-7842.
69. Roux, C.; Bhatt, F.; Foret, J.; de Courcy, B.; Gresh, N.; Piquemal, J.-P.; Jeffery, C. J.; Salmon, L. The reaction mechanism of type I phosphomannose isomerases: New information from inhibition and polarizable molecular mechanics studies. Proteins, 2011, 79(1), 203-220.
70. Gupta, A. K.; Skinner, A. R. Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol., 2003, 42(S1), 3-9.
71. Subissi, A.; Monti, D.; Togni, G.; Mailland, F. Ciclopirox: Recent Nonclinical and Clinical Data Relevant to its Use as a Topical Antimycotic Agent. Drugs, 2010, 70(16), 2133-2152.
72. Leem, S. H.; Park, J. E.; Kim, I. S.; Chae, J. Y.; Sugino, A.; Sunwoo, Y. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol. Cells, 2003, 15(1), 55-61.
73. Sharma, N.; Kumari, M.; Kumar, V.; Chaudhry, S. C. Synthesis, structural characterisation and antibacterial activity of bis(1- phenyl-1,3-butanedionato)non-oxovanadium(IV) hydroxamates. J. Enzym. Inhib. Med. Chem., 2010, 25(5), 708-714.
74. Darwish, I. S.; Miller, M. J. Synthesis of the Antifungal Agent Neoenactin A and Its N-Deshydroxy Derivative. J. Org. Chem., 1994, 59(2), 451-454.
75. Vértesy, L.; Aretz, W.; Fehlhaber, H.-W.; Kogler, H. 3. Salmycin A-D, antibiotika aus Streptomyces violaceus, DSM 8286, mit Siderophor- Aminoglycosid-Struktur. Helv. Chim. Acta, 1995, 78, 46-60.
76. Pramanik, A.; Braun, V. Albomycin Uptake via a Ferric Hydroxamate Transport System of Streptococcus pneumoniae R6. J. Bacteriol., 2006, 188(11), 3978-3886.
77. Rao, S.; Starr, R. L.; Morris, M. G.; Lin, W.-J. Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains. Foodborne Pathog. Dis., 2007, 4(2), 201-207.
78. Hicks, R. P.; Hartell, M. G.; Nichols, D. A.; Bhattacharjee, A. K.; van Hamont, J. E.; Skillman, D. R. The medicinal chemistry of botulinum, ricin and anthrax toxins. Curr. Med. Chem., 2005, 12(6), 667-690.
79. Simpson, L. L. Identification of the Major Steps in Botulinum Toxin Action. Ann. Rev. Pharmacol. Toxicol., 2004, 44, 167.
80. Smith, G. R.; Caglič, D.; Čapek, P.; Zhang, Y.; Godbole, S.; Reitz, A. B.; Dickerson, T. J. Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the β-exosite. Bioorg. Med. Chem. Lett., 2012, 22(11), 3754-3757.
81. Capková, K.; Yoneda, Y.; Dickerson, T. J.; Janda, K. D. Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(23), 6463-6466.
82. Follmer, C. Ureases as a target for the treatment of gastric and urinary infections. J. Clin. Pathol., 2010, 63(5), 424-430.
83. Barros, T. G.; Williamson, J. S.; Antunes, O. A. C.; Muri, E. M. F. Hydroxamic acids designed as inhibitors of urease. Lett. Drug Des. Discov., 2009, 6(3), 186-192.
84. Supuran, C. T.; Briganti, F.; Mincione, G.; Scozzafava, A. Protease inhibitors: Synthesis of L-alanine hydroxamate sulfonylated derivatives as inhibitors of Clostridium histolyticum collagenase. J. Enzym. Inhib., 2000, 15(2), 111-128.
85. Khan, M. T. H.; Fuskevåg, O.-M.; Sylte, I. Discovery of Potent Thermolysin Inhibitors Using Structure Based Virtual Screening and Binding Assays. J. Med. Chem., 2008, 52(1), 48-61.
86. Jin, Y. H.; Kim, D. H. Inhibition stereochemistry of hydroxamate inhibitors for thermolysin. Bioorg. Med. Chem. Lett., 1998, 8(24), 3515-3518.
87. Barbaric, M.; Ursic, S.; Pilepic, V.; Zorc, B.; Hergold-Brundic, A.; Nagl, A.; Grdisa, M.; Pavelic, K.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E.; Mintas, M. Synthesis, X-ray Crystal Structure Study, and Cytostatic and Antiviral Evaluation of the Novel Cycloalkyl-N-aryl-hydroxamic Acids. J. Med. Chem., 2005, 48(3), 884-887.
88. Rajic, Z.; Butula, I.; Zorc, B.; Pavelic, S. K.; Hock, K.; Pavelic, K.; Naesens, L.; De Clercq, E.; Balzarini, J.; Przyborowska, M.; Ossowski, T.; Mintas, M. Cytostatic and Antiviral Activity Evaluations of Hydroxamic Derivatives of Some Non-steroidal Anti-inflammatory Drugs. Chem. Biol. Drug Des., 2009, 73(3), 328-338.
89. Shan, L.; Deng, K.; Shroff, Neeta S.; Durand, Christine M.; Rabi, S. A.; Yang, H.-C.; Zhang, H.; Margolick, Joseph B.; Blankson, Joel N.; Siliciano, Robert F. Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. Immunity, 2012, 36(3), 491-501.
90. Wightman, F.; Ellenberg, P.; Churchill, M.; Lewin, S. R. HDAC inhibitors in HIV. Immunol. Cell Biol., 2012, 90(1), 47-54.
91. Okada, T.; Sawada, T.; Kubota, K. Deferoxamine enhances antiproliferative effect of interferon-γ against hepatocellular carcinoma cells. Cancer Lett., 2007, 248(1), 24-31.
92. Zhou, H.; Shen, T.; Luo, Y.; Liu, L.; Chen, W.; Xu, B.; Han, X.; Pang, J.; Rivera, C. A.; Huang, S. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer, 2010, 127(10), 2467-2477.
93. Elford, H. L.; Wampler, G. L.; van't Riet, B. New Ribonucleotide Reductase Inhibitors with Antineoplastic Activity. Cancer Res., 1979, 39(3), 844-851.
94. Lombardi, P. M.; Cole, K. E.; Dowling, D. P.; Christianson, D. W. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol., 2011, 21, 1-9.
95. Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol., 2011, DOI: 10.1038/icb.2011.100.
96. Rius, M.; Lyko, F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene, 2011.
97. Nebbioso, A.; Carafa, V.; Benedetti, R.; Altucci, L. Trials with 'epigenetic' drugs: An update. Mol. Oncol., 2012, DOI: 10.1016/j.molonc.2012.09.004.
98. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist, 2007, 12(10), 1247-1252.
99. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. Bioorg. Med. Chem., 2007, 15(6), 2223-2268.
100. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 2011, 278(1), 16-27.
101. Rothenberg, M. L.; Nelson, A. R.; Hande, K. R. New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist, 1998, 3(4), 271-274.
102. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev., 2003, 23(2), 146-189.
103. Guler, O. O.; de Simone, G.; Supuran, C. T. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr. Med. Chem., 2010, 17(15), 1516-1526.
104. Santos, M. A.; Marques, S.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorg. Med. Chem. Lett., 2007, 17(6), 1538-1543.
105. Hyde, C. A. C.; Missailidis, S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumorangiogenesis. Int. Immunopharmacol., 2009, 9(6), 701-715.
106. Fürstner, A.; Feyen, F.; Prinz, H.; Waldmann, H. Synthesis and evaluation of the antitumor agent TMC-69-6H and a focused library of analogs. Tetrahedron, 2004, 60(43), 9543-9558.
107. Kawai, M.; BaMaung, N. Y.; Fidanze, S. D.; Erickson, S. A.; Tedrow, J. S.; Sanders, W. J.; Vasudevan, A.; Park, C.; Hutchins, C.; Comess, K. M.; Kalvin, D.; Wang, J.; Zhang, Q.; Lou, P.; Tucker-Garcia, L.; Bouska, J.; Bell, R. L.; Lesniewski, R.; Henkin, J.; Sheppard, G. S. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg. Med. Chem. Lett., 2006, 16(13), 3574-3577.
108. Gonzalez-Bulnes, P.; Gonzalez-Roura, A.; Canals, D.; Delgado, A.; Casas, J.; Llebaria, A. 2-Aminohydroxamic acid derivatives as inhibitors of Bacillus cereus phosphatidylcholine preferred phospholipase C PC-PLCBc. Bioorg. Med. Chem., 2010, 18(24), 8549-8555.
109. Stoermer, D.; Liu, Q.; Hall, M.; Flanary, J.; Thomas, A.; Rojas, C.; Slusher, B.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-based inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett., 2003, 13(13), 2097-2100.
110. Heightman, T. D. Chemical Biology of Lysine Demethylases. Curr. Chem. Genomics, 2011, 5(Suppl 1-M3), 62-71.
111. Rodrigo, C. M.; Cencic, R.; Roche, S. P.; Pelletier, J.; Porco, J. A. Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies. J. Med. Chem., 2011, 55(1), 558-562.
112. Leone, S.; Ottani, A.; Bertolini, A. Dual acting anti-inflammatory drugs. Curr. Top. Med. Chem., 2007, 7(3), 265-275.
113. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. Pharmacol. Rev., 2004, 56(3), 387-437.
114. Andreou, A.; Feussner, I. Lipoxygenases - Structure and reaction mechanism. Phytochemistry, 2009, 70(13-14), 1504-1510.
115. Huang, F.-C.; Shoupe, T. S.; Lin, C. J.; Lee, T. D. Y.; Chan, W.-K.; Tan, J.; Schnapper, M.; Suh, J. T.; Gordon, R. J.; Sonnino, P. A.; Sutherland, C. A.; Inwegen, R. G. V.; Coutts, S. M. Differential Effects of a Series of Hydroxamic Acid Derivatives on 5-Lipoxygenase and Cyclooxygenase from Neutrophils and 12-Lipoxygenase from Platelets and Their in Vivo Effects on Inflammation and Anaphylaxis. J. Med. Chem., 1989, 32(8), 1836-1842.
116. Bahia, M.; Silakari, O. Strategy for generation of new TACE inhibitors: pharmacophore and counter pharmacophore modeling to remove nonselective hits. Med. Chem. Res., 2010, 1-9 (Article in Press).
117. Feng, W.-f.; Zhao, Y.-b.; Huang, W.; Yang, Y.-z. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity. J. Enzym. Inhib. Med. Chem., 2010, 25(4), 459-466.
118. Stanetty, C.; Czollner, L.; Koller, I.; Shah, P.; Gaware, R.; Cunha, T. D.; Odermatt, A.; Jordis, U.; Kosma, P.; Claßen-Houben, D. Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11[beta]-hydroxysteroid dehydrogenase 2 inhibitors. Bioorg. Med. Chem., 2010, 18(21), 7522-7541.
119. Fournié-Zaluski, M.-C.; Coulaud, A.; Bouboutou, R.; Chaillet, P.; Devin, J.; Waksman, G.; Costentin, J.; Roques, B. P. New Bidentates as Full Inhibitors of Enkephalin-Degrading Enzymes: Synthesis and Analgesic Properties. J. Med. Chem., 1985, 28(9), 1158-1169.
120. Halili, M. A.; Andrews, M. R.; Sweet, M. J.; Fairlie, D. P. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem., 2009, 9(3), 309-319.
121. Penning, T. D. Inhibitors of Leukotriene A4 (LTA4) Hydrolase as Potential Anti Inflammatory Agents. Curr. Pharm. Des., 2001, 7(3), 163-179.
122. Royce, S. G.; Karagiannis, T. C. Histone Deacetylases and Their Role in Asthma. J. Asthma, 2012, 49(2), 121-8.
123. Mothet, J.-P.; Parent, A. T.; Wolosker, H.; Brady Jr., R. O.; Linden, D. J.; Ferris, C. D.; Rogawski, M. A.; Snyder, S. H. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Nat. Acad. Sci. USA, 2000, 97(9), 4926-4931.
124. Sasabe, J.; Chiba, T.; Yamada, M.; Okamoto, K.; Nishimoto, I.; Matsuoka, M.; Aiso, S. D-Serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J., 2007, 26(18), 4149-4159.
125. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Okada, S.-I.; Komatsu, N.; Okamura, N.; Koike, K.; Koizumi, H.; Kumakiri, C.; Imai, K.; Iyo, M. Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 2004, 28(2), 385-388.
126. Hoffman, H. E.; Jirásková, J.; Cígler, P.; Sanda, M.; Schraml, J.; Konvalinka, J. Hydroxamic Acids As a Novel Family of Serine Racemase Inhibitors: Mechanistic Analysis Reveals Different Modes of Interaction with the Pyridoxal-5'-phosphate Cofactor. J. Med. Chem., 2009, 52(19), 6032-6041.
127. Thomas, A. G.; Rojas, C. J.; Hill, J. R.; Shaw, M.; Slusher, B. S. Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibition. Anal. Biochem., 2010, 404(1), 94-96.
128. Mesters, J. R.; Hilgenfeld, R. In: Handbook of Metalloproteins; John Wiley & Sons, Ltd: 2006; pp.
129. Ptak, C.; Petronis, A. Epigenetic approaches to psychiatric disorders. Dialogues Clin. Neurosci., 2010, 12(1), 23-33.
130. Scuteri, A.; Ravasi, M.; Pasini, S.; Bossi, M.; Tredici, G. Mesenchymal stem cells support dorsal root ganglion neurons survival by inhibiting the metalloproteinase pathway. Neuroscience, 2011, 172, 12-19.
131. Gibson, C. L.; Murphy, S. P. Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. J. Neurochem., 2010, 115(4), 806-813.
132. McKinsey, T. A. Therapeutic Potential for HDAC Inhibitors in the Heart. Ann. Rev. Pharmacol. Toxicol., 2012, 52(1), 303-319.
133. Moncada, S.; Higgs, E. A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J., 1995, 9(13), 1319-1330.
134. Stuehr, D. J. Mammalian nitric oxide synthases. Biochem. Biophys. Acta Bioenergetics, 1999, 1411(2-3), 217-230.
135. Marmion, C. J.; Murphy, T.; Docherty, J. R.; Nolan, K. B. Hydroxamic acids are nitric oxide donors. Facile formation of ruthenium(II)-nitrosyls and NO-mediated activation of guanylate cyclase by hydroxamic acids. Chem. Commun., 2000, (13), 1153-1154.
136. Vystorop, I. V.; Konovalova, N. P.; Nelyubina, Y. V.; Varfolomeev, V. N.; Fedorov, B. S.; Sashenkova, T. E.; Berseneva, E. N.; Lyssenko, K. A.; Kostyanovskyc, R. G. Cyclic hydroxamic acids derived from α-amino acids - 1. Regioselective synthesis, structure, NO-donor and antimetastatic activities of spirobicyclic hydroxamic acids derived from glycine and DL-alanine. Russ. Chem. Bull. Int. Ed., 2010, 59(1), 127-135.
137. Paulis, L.; Unger, T. Novel therapeutic targets for hypertension. Nat. Rev. Cardiol., 2010, 7(8), 431-441.
138. Kodani, S.; Ohnishi-Kameyama, M.; Yoshida, M.; Ochi, K. A New Siderophore Isolated from Streptomyces sp. TM-34 with Potent Inhibitory Activity Against Angiotensin-Converting Enzyme. Eur. J. Org. Chem., 2011, 2011(17), 3191-3196.
139. Bailey, S.; Fish, P.; Billotte, S.; Bordner, J.; Greiling, D.; James, K.; McElroy, A.; Mills, J.; Reed, C.; Webster, R. Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg. Med. Chem. Lett., 2008, 18(24), 6562-6567.
140. Reid, R. R.; Mogford, J. E.; Butt, R.; deGiorgio-Miller, A.; Mustoe, T. A. Inhibition of procollagen C-proteinase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen., 2006, 14(2), 138-141.
141. Alcaraz, M. J.; Megías, J.; García-Arnandis, I.; Clérigues, V.; Guillén, M. I. New molecular targets for the treatment of osteoarthritis. Biochem. Pharmacol., 2010, 80(1), 13-21.
142. Nuti, E.; Casalini, F.; Avramova, S. I.; Santamaria, S.; Cercignani, G.; Marinelli, L.; La Pietra, V.; Novellino, E.; Orlandini, E.; Nencetti, S.; Tuccinardi, T.; Martinelli, A.; Lim, N.-H.; Visse, R.; Nagase, H.; Rossello, A. N-O-isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J. Med. Chem., 2009, 52(15), 4757-4773.
143. Noe, M. C.; Natarajan, V.; Snow, S. L.; Mitchell, P. G.; Lopresti- Morrow, L.; Reeves, L. M.; Yocum, S. A.; Carty, T. J.; Barberia, J. A.; Sweeney, F. J.; Liras, J. L.; Vaughn, M.; Hardink, J. R.; Hawkins, J. M.; Tokar, C. Discovery of 3,3-dimethyl-5- hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett., 2005, 15(11), 2808-2811.
144. Sonnemann, J.; Greßmann, S.; Becker, S.; Wittig, S.; Schmudde, M.; Beck, J. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumor cells in vitro. Cancer Chemther. Pharmacol., 2010, 66(3), 611-616.
145. Tommasi, R. A.; Weiler, S.; McQuire, L. W.; Rogel, O.; Chambers, M.; Clark, K.; Doughty, J.; Fang, J.; Ganu, V.; Grob, J.; Goldberg, R.; Goldstein, R.; LaVoie, S.; Kulathila, R.; Macchia, W.; Melton, R.; Springer, C.; Walker, M.; Zhang, J.; Zhu, L.; Shultz, M. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. Bioorg. Med. Chem. Lett., 2011, 21(21), 6440-5.
146. Dejonckheere, E.; Vandenbroucke, R. E.; Libert, C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today, 2011, 16(17-18), 762-778.
147. Vandenbroucke, R. E.; Dejonckheere, E.; Libert, C. A therapeutic role for MMP inhibitors in lung diseases? Eur. Resp. J., 2011, 38(5), 1200-14.
148. Chen, W.-P.; Bao, J.-P.; Hu, P.-F.; Feng, J.; Wu, L.-D. Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis. Mol. Biol. Rep., 2010, 37(8), 3967-3972.
149. Leissring, M. A.; Malito, E.; Hedouin, S.; Reinstatler, L.; Sahara, T.; Abdul-Hay, S. O.; Choudhry, S.; Maharvi, G. M.; Fauq, A. H.; Huzarska, M.; May, P. S.; Choi, S.; Logan, T. P.; Turk, B. E.; Cantley, L. C.; Manolopoulou, M.; Tang, W.-J.; Stein, R. L.; Cuny, G. D.; Selkoe, D. J. Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin. PLoS One, 2010, 5(5), e10504.
150. Georgiades, S.; Mak, L.; Angurell, I.; Rosivatz, E.; Firouz Mohd Mustapa, M.; Polychroni, C.; Woscholski, R.; Vilar, R. Identification of a potent activator of Akt phosphorylation from a novel series of phenolic, picolinic, pyridino, and hydroxamic zinc(II) complexes. J. Biol. Inorg. Chem., 2011, 16(2), 195-208.
151. Villalta-Romero, F.; Gortat, A.; Herrera, A. E.; Arguedas, R.; Quesada, J.; de Melo, R. L.; Calvete, J. J.; Montero, M.; Murillo, R.; Rucavado, A.; Gutiérrez, J. M.; Pérez-Payá, E. Identification of New Snake Venom Metalloproteinase Inhibitors Using Compound Screening and Rational Peptide Design. Med. Chem. Lett., 2012, 3(7), 540-543.
152. Henderson, J. L.; Sawant-Basak, A.; Tuttle, J. B.; Dounay, A. B.; McAllister, L. A.; Pandit, J.; Rong, S.; Hou, X.; Bechle, B. M.; Kim, J.-Y.; Parikh, V.; Ghosh, S.; Evrard, E.; Zawadzke, L. E.; Salafia, M. A.; Rago, B.; Obach, R. S.; Clark, A.; Fonseca, K. R.; Chang, C.; Verhoest, P. R. Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics. Med. Chem. Commun., 2012, DOI: 10.1039/C2MD20166F.
153. Vontzalidou, A.; Chaita, E.; Aligiannis, N.; Makropoulou, M.; Kalpoutzakis, E.; Termentzi, A.; Guldbrandsen, N.; Hamburger, M.; Dumontet, V.; Pamlard, O.; Guéritte, F.; Skaltsounis, A. L. Evaluation of natural products as potential cosmetic agents with tyrosinase inhibition activity. Planta Med., 2012, 78(11), PA11.
154. Sanderson, L.; Taylor, G. W.; Aboagye, E. O.; Alao, J. P.; Latigo, J. R.; Coombes, R. C.; Vigushin, D. M. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab. Dispos., 2004, 32(10), 1132-1138.
155. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously. Clin. Cancer Res., 2003, 9(10), 3578-3588.
156. Dalvie, D.; Cosker, T.; Boyden, T.; Zhou, S.; Schroeder, C.; Potchoiba, M. J. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)- benzenesulfonylamino]tetrahydropyran-4- carboxylic acid hydroxyamide (CP-544439), in rats and dogs: Assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Drug Metab. Dispos., 2008, 36(9), 1869-1883.
157. Mulder, G. J.; Meerman, J. H. N. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: The role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. Environ. Health Perspect., 1983, Vol. 49, 27-32.
158. Parise, R. A.; Holleran, J. L.; Beumer, J. H.; Ramalingam, S.; Egorin, M. J. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J. Chromatogr. B, 2006, 840(2), 108-115.
159. Ghosh, K. K.; Patle, S. K.; Sharma, P.; Rajput, S. K. A Comparison between the Acid-Catalysed Reactions of Some Dihydroxamic Acids, Monohydroxamic Acids and Desferal. Bull. Chel. Soc. Japan, 2003, 76(2), 283-290.
160. Flipo, M.; Charton, J.; Hocine, A.; Dassonneville, S.; Deprez, B.; Deprez-Poulain, R. Hydroxamates: Relationships between structure and plasma stability. J. Med. Chem., 2009, 52(21), 6790-6802.
161. Thomas, M.; Rivault, F.; Tranoy-Opalinski, I.; Roche, J.; Gesson, J.-P.; Papot, S. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β- galactoside for application in selective prodrug chemotherapy. Bioorg. Med. Chem. Lett., 2007, 17(4), 983-986.
162. Schlimme, S.; Hauser, A.-T.; Carafa, V.; Heinke, R.; Kannan, S.; Stolfa, D. A.; Cellamare, S.; Carotti, A.; Altucci, L.; Jung, M.; Sippl, W. Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors. ChemMedChem, 2011, 6(7), 1193-1198.
163. Failes, T. W.; Cullinane, C.; Diakos, C. I.; Yamamoto, N.; Lyons, J. G.; Hambley, T. W. Studies of a Cobalt(III) Complex of the MMP Inhibitor Marimastat: A Potential Hypoxia-Activated Prodrug. Chem. Eur. J., 2007, 13(10), 2974-2982.
164. Yamamoto, N.; Renfrew, A. K.; Kim, B. J.; Bryce, N. S.; Hambley, T. W. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. J. Med. Chem., 2012.
165. Failes, T. W.; Hambley, T. W. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. J. Inorg. Biochem., 2007, 101(3), 396-403.
166. Clarke, A. J.; Yamamoto, N.; Jensen, P.; Hambley, T. W. Iron(iii) complexes of fluorescent hydroxamate ligands: preparation, properties, and cellular processing. Dalton Trans., 2009, (48), 10787-10798.
167. Graf, N.; Lippard, S. J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Delivery Rev., 2012, 64(11), 993-1004.
168. Yang, K.; Lou, B. Molecular Diversity of Hydroxamic Acids: Part I. Solution- and Solid-Phase Synthesis. Mini-Rev. Med. Chem., 2003, 3(4), 349-360.
169. Giacomelli, G.; Porcheddu, A.; Salaris, M. Simple One-Flask Method for the Preparation of Hydroxamic Acids. Org. Lett., 2003, 5(15), 2715-2717.
170. Devocelle, M.; McLoughlin, B. M.; Sharkey, C. T.; Fitzgerald, D. J.; Nolan, K. B. A convenient parallel synthesis of low molecular weight hydroxamic acids using polymer-supported 1- hydroxybenzotriazole. Org. Biomol. Chem., 2003, 1(5), 850-853.
171. Kurz, T.; Pein, M. K.; Marek, L.; Behrendt, C. T.; Spanier, L.; Kuna, K.; Brücher, K. Microwave-assisted conversion of 4- nitrophenyl esters into O-protected hydroxamic acids. Eur. J. Org. Chem., 2009, (18), 2939-2942.
172. Krchnák, V. Solid-phase synthesis of biologically interesting compounds containing hydroxamic acid moiety. Mini-Rev. Med. Chem., 2006, 6(1), 27-36.
173. Maurer, P. J.; Miller, M. J. Microbial Iron Chelators: Total Synthesis of Aerobactin and Its Constituent Amino Acid, N6- Acetyl-N6-hydroxy lysine. J. Am. Chem. Soc., 1982, 104(11), 3096-3101.
174. Kobayashi, K.; Oishi, S.; Kobayashi, Y.; Ohno, H.; Tsutsumi, H.; Hata, Y.; Fujii, N. Synthesis and application of an Nδ-acetyl-Nδ- hydroxyornithine analog: Identification of novel metal complexes of deferriferrichrysin. Bioorg. Med. Chem., 2012, 20(8), 2651-2655.
175. Dimise, E. J.; Condurso, H. L.; Stoker, G. E.; Bruner, S. D. Synthesis and structure confirmation of fuscachelins A and B, structurally unique natural product siderophores from Thermobifida fusca. Org. Biomol. Chem., 2012, 10(28), 5353-5356.
176. Walz, A. J.; Miller, M. J. β-Lactams in synthesis: short syntheses of cobactin analogs. Tetrahedron Lett., 2007, 48(29), 5103-5105.
177. Ga-rtner, M.; Ja-kel, M.; Achatz, M.; Sonnenschein, C.; Tverskoy, O.; Helmchen, G. n. Enantioselective Iridium-Catalyzed Allylic Substitutions with Hydroxamic Acid Derivatives as NNucleophiles. Org. Lett., 2011, 13(11), 2810-2813.
178. Sani, M.; Candiani, G.; Pecker, F.; Malpezzi, L.; Zanda, M. Novel highly potent, structurally simple γ-trifluoromethyl γ-sulfone hydroxamate inhibitor of stromelysin-1 (MMP-3). Tetrahedron Lett., 2005, 46(14), 2393-2396.
179. Bertrand, S.; Duval, O.; Hélesbeux, J.-J.; Larcher, G.; Richomme, P. Synthesis of the trans-fusarinine scaffold. Tetrahedron Lett., 2010, 51(16), 2119-2122.
180. Widmer, J.; Keller-Schierlein, W. Stoffwechselprodukte von Mikroorganismen - Synthesen in der Sideramin-Reihe: Rhodotorulasäure und Dimerumsäure. Helv. Chim. Acta, 1974, 57(7), 1904-1912.
181. Ye, Y.; Liu, M.; Kao, J. L.-K.; Marshall, G. R. Peptide-Bond Modification for Metal Coordination: Peptides Containing Two Hydroxamate Groups. Biopolymers, 2003, 71(4), 489-515.
182. Miyata, O.; Koizumi, T.; Asai, H.; Iba, R.; Naito, T. Imino 1,2- Wittig rearrangement of hydroximates and its application to synthesis of cytoxazone. Tetrahedron, 2004, 60(17), 3893-3914.
183. Genet, J.-P.; Thorimbert, S.; Touzin, A.-M. Palladium (0) catalyzed amination with N,O-bis-ter-Boc hydroxylamine. Synthesis of (+)- N6-hydroxylysine. Tetrahedron Lett., 1993, 34(7), 1159-1162.
184. Wu, T. Y. H.; Hassig, C.; Wu, Y.; Ding, S.; Schultz, P. G. Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg. Med. Chem. Lett., 2004, 14(2), 449-453.
185. Roosenberg II, J. M.; Miller, M. J. Total Synthesis of the Siderophore Danoxamine. J. Org. Chem., 2000, 65(16), 4833-4838.
186. Arribas, C.; Carreño, M. C.; García-Ruano, J. L.; Rodríguez, J. F.; Santos, M.; Sanz-Tejedor, M. A. First Asymmetric Hetero Diels- Alder Reaction of 1-Sulfinyl Dienes with Nitroso Derivatives. A New Entry to the Synthesis of Optically Pure 1,4-Imino-L-ribitol Derivatives. Org. Lett., 2000, 2(20), 3165-3168.
187. Davies, S. J.; Ayscough, A. P.; Beckett, R. P.; Bragg, R. A.; Clements, J. M.; Doel, S.; Grew, C.; Launchbury, S. B.; Perkins, G. M.; Pratt, L. M.; Smith, H. K.; Spavold, Z. M.; W. Thomas, S.; Todd, R. S.; Whittaker, M. Structure-Activity Relationships of the Peptide Deformylase Inhibitor BB-3497: Modification of the Methylene Spacer and the P1' Side Chain. Bioorg. Med. Chem. Lett., 2003, 13(16), 2709-2713.
188. Sakamoto, T.; Li, H.; Kikugawa, Y. A Total Synthesis of Nannochelin A. A Short Route to Optically Active Nω-Hydroxy-ω- amino Acid Derivatives. J. Org. Chem., 1996, 61(24), 8496-8499.
189. Basso, A.; Banfi, L.; Guanti, G.; Riva, R.; Riu, A. Ugi multicomponent reaction with hydroxylamines: An efficient route to hydroxamic acid derivatives. Tetrahedron Lett., 2004, 45(32), 6109-6111.
190. Atkinson, J.; Arnason, J.; Campos, F.; Niemeyer, H. M.; Bravo, H. R. In: Synthesis and Chemistry of Agrochemicals III.
191. Macías, F. A.; Marín, D.; Oliveros-Bastidas, A.; Chinchilla, D.; Simonet, A. M.; Molinillo, J. M. G. Isolation and synthesis of allelochemicals from gramineae: Benzoxazinones and related compounds. J. Agric. Food Chem., 2006, 54(4), 991-1000.
192. Miller, M. J. Syntheses and Therapeutic Potential of Hydroxamic Acid Based Siderophores and Analogs. Chem. Rev., 1989, 89(7), 1563-1579.
193. McAllister, L. A.; Bechle, B. M.; Dounay, A. B.; Evrard, E.; Gan, X.; Ghosh, S.; Kim, J.-Y.; Parikh, V. D.; Tuttle, J. B.; Verhoest, P. R. A General Strategy for the Synthesis of Cyclic N-Aryl Hydroxamic Acids via Partial Nitro Group Reduction. J. Org. Chem., 2011, 76(9), 3484-3497.
194. Polonski, T.; Chimiak, A. Oxidation of amino acid esters into Nhydroxyamino acid derivatives. Tetrahedron Lett., 1974, 15(28), 2453-2456.
195. Hu, J.; Miller, M. J. A New Method for the Synthesis of N-Acetyl- N-hydroxy-L-lysine, the Iron-Binding Constituent of Several Important Siderophores. J. Org. Chem., 1994, 59, 4858-4861.
196. Fields, J. D.; Kroop, P. J. Surface-Mediated Reactions. 9. Selective Oxidation of Primary and Secondary Amines to Hydroxylamines. J. Org. Chem., 2000, 65(19), 5937-5941.
197. Wang, Q. X.; Hing, J.; Phanstiel IV, O. An Improved Synthesis of O-Benzoyl Protected Hydroxamates. J. Org. Chem., 1997, 62(23), 8104-8108.
198. Medina, S. I.; Wu, J.; Bode, J. W. Nitrone protecting groups for enantiopure N-hydroxyamino acids: Synthesis of N-terminal peptide hydroxylamines for chemoselective ligations. Org. Biomol. Chem., 2010, 8(15), 3405-3417.
199. Matlin, S. A.; Sammes, P. G.; Upton, R. M. The oxidation of trimethylsilylated amides to hydroxamic acids. J. Chem. Soc. Perkin Trans. 1, 1979, 2481-2487.
200. Banerjee, R.; King, S. B. Synthesis of Cyclic Hydroxamic Acids through -NOH Insertion of Ketones. Org. Lett., 2009, 11(20), 4580-4583.
201. Liu, Y.; Jacobs, H. K.; Gopalan, A. S. A new approach to cyclic hydroxamic acids: intramolecular cyclization of N-benzyloxy carbamates with carbon nucleophiles. Tetrahedron, 2011, 67(12), 2206-2214.